Obinutuzumab Combined With Lenalidomide(GL) in Recurrent or Refractory Marginal Zone Lymphoma (MZL)
Status:
Recruiting
Trial end date:
2028-05-31
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center clinical study to enroll 59 patients with relapsed and
refractory MZL. The study was designed to assess the efficacy and safety of the combination
of obintuzumab and lenalidomide in the treatment of relapsed and refractory(R/R) marginal
zone lymphoma (MZL).